Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08XGI
|
||||
Former ID |
DNC004123
|
||||
Drug Name |
(1-Phenethyl-piperidin-4-yl)-phenyl-methanone
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C20H23NO
|
||||
Canonical SMILES |
C1CN(CCC1C(=O)C2=CC=CC=C2)CCC3=CC=CC=C3
|
||||
InChI |
1S/C20H23NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19H,11-16H2
|
||||
InChIKey |
GEFOLRNTTIQKBZ-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Inhibitor | [1] | |
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Gap junction | |||||
Serotonergic synapse | |||||
Inflammatory mediator regulation of TRP channels | |||||
PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
Reactome | Serotonin receptors | ||||
G alpha (q) signalling events | |||||
WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
SIDS Susceptibility Pathways | |||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References | |||||
REF 1 | J Med Chem. 2001 Feb 15;44(4):477-501.Current and novel approaches to the drug treatment of schizophrenia. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.